2018-01-15
Abirateron in combinatie met androgeendeprivatietherapie bij patiënten met hormoonnaïef gemetastaseerd prostaatcarcinoom: Is het tijdperk van androgeendeprivatie-monotherapie voorbij?
Publication
Publication
Abiraterone and androgen-deprivation therapy for hormone-sensitive metastatic prostate cancer: Is the era of androgen deprivation monotherapy over?
Tijdschrift voor Urologie , Volume 8 - Issue 4 p. 60- 65
Two randomized trials have shown that abiraterone plus prednisone and androgen-deprivation therapy (ADT) improved survival as compared with ADT alone in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC) (hazard ratio 0.62–0.63). The most important side-effects (hypokalemia and hypertension) were mild (mostly grade 1–2) and easy to manage. For patients with high-risk locally advanced disease or lymph node metastases abiraterone plus prednisone and ADT increased progression-free survival. However, the data is still immature to show overall survival benefit in this patient subgroup. For patients with mHSPC, combination therapy with abiraterone plus prednisone and ADT can be considered a new standard of care.
Additional Metadata | |
---|---|
, | |
doi.org/10.1007/s13629-017-0196-x, hdl.handle.net/1765/128295 | |
Tijdschrift voor Urologie | |
Organisation | Department of Orthopaedics |
van Soest, R. J., van Leeuwen, P.J., Boormans, J., & Bangma, C. (2018). Abirateron in combinatie met androgeendeprivatietherapie bij patiënten met hormoonnaïef gemetastaseerd prostaatcarcinoom: Is het tijdperk van androgeendeprivatie-monotherapie voorbij?. Tijdschrift voor Urologie, 8(4), 60–65. doi:10.1007/s13629-017-0196-x |